|
As reported in the New York Times, we walked a good distance towards understanding the root cause of metastasis – the spread of cancer to many organs in addition to the organ that hosts the primary tumor. Scientists have already discovered genes that enables the micro- circulating cancerous cells to successfully colonize on other organs made of cells that totally differ from their original host organ. This is good news among many other good news our subscribers will find in the next Prohost N-letter.
In Today’s news, Amylin Pharmaceuticals (AMLN) and Eli Lilly lifted restrictions on their diabetes drug this week after a cartridge shortage forced the two companies to ask doctors to limit the number of patients they start on the regimen. This news is great for two reasons. The first is that the shortage of cartridges, which is a temporary setback that caused a decline in the stock is an indication of how excellent are the drug sales. The second reason for enthusiasm is the ability of the firms to quickly solve the problem.
This is good news for AMLN.
In the news also, ARIAD Pharmaceuticals. (ARIA) announced issuance of a U.S. patent covering its novel mTOR inhibitors, including its lead cancer product candidate - AP23573 - and uses of these compounds to treat various cancers and to prevent reblockage at sites of vascular injury following stent-assisted angioplasty. U.S. Patent No. 7,091,213 provides coverage through the year 2023. AP23573 is set to enter a global Phase 3 clinical trial in patients with advanced sarcomas.
Ariad’s drugs that target mTOR are overlooked by many analysts who prefer to base their evaluation only on financial reports.
Read More: ARIAD Announces Issuance of Key Patent Covering Its mTOR Inhibitors and Treatment Methods in Cancer and Restenosis
As Good as the most powerful antibiotic
GENZYME (GENZ): Results from phase 2 trial of Tolevamer, an investigational polymer therapy for patients with Clostridium difficile-associated diarrhea (CDAD), published in the August 15 issue of Clinical Infectious Diseases show promising results equal to the effect of Vancomycin. Tolevamer is a novel therapy that could be the first non-antibiotic treatment approved for CDAD, a sometimes deadly form of infectious diarrhea caused by the bacterium C. difficile. Tolevamer is designed to bind and remove from the body toxins released by C. difficile that damage the large intestine.
This is good news
Read More: Results of Phase 2 Study of Tolevamer for C. difficile-Associated Diarrhea Published in Clinical Infectious Diseases
|
